Efficacy of liraglutide added to sodium-glucose cotransporter-2 inhibitors in type 2 diabetes, stratified by baseline characteristics: Post-hoc analysis of LIRA-ADD2SGLT2i

Lawrence Blonde, Udi Fainberg, Margit S Kaltoft, Ofri Mosenzon, Chethana Ramesh, Rosangela Rea, Lawrence Blonde, Udi Fainberg, Margit S Kaltoft, Ofri Mosenzon, Chethana Ramesh, Rosangela Rea

Abstract

Aims: The LIRA-ADD2SGLT2i trial demonstrated that liraglutide + sodium-glucose cotransporter-2 inhibitors (SGLT2is) ± metformin significantly improved glycaemic control (not body weight) versus placebo in adults with type 2 diabetes (T2D). This post-hoc analysis assessed whether baseline characteristics influenced these findings.

Materials and methods: LIRA-ADD2SGLT2i (NCT02964247) was a placebo-controlled, double-blind, multinational trial, wherein participants received liraglutide (≤1.8 mg/day) or placebo (randomized 2:1). Changes from baseline to week 26 in haemoglobin A1c (HbA1c), body weight and waist circumference stratified by HbA1c, body mass index (BMI), diabetes duration, duration of pre-trial SGLT2i use and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) were analysed. These five baseline characteristics were divided into tertiles, and the treatment effect was evaluated using the trial product estimand.

Results: Data from all 303 participants were analysed. There was a significant interaction between baseline HbA1c tertiles (7.0%-<7.6%; 7.6%-8.1%; ≥8.2%-9.5%) and glycaemic control at week 26 (p[interaction] = .011), with the lowest HbA1c estimated treatment difference (95% confidence interval) observed in patients with lowest baseline HbA1c [-0.20% (-0.59, 0.19); -0.68% (-1.03, -0.33); -0.98% (-1.33, -0.64), respectively]. There were no significant interactions in glycaemic control across baseline BMI, diabetes duration, insulin resistance determined by HOMA-IR or SGLT2i use duration (p[interaction] > .05, all). Across the five characteristics assessed, no significant interactions were found for body weight or waist circumference changes from baseline (p[interaction] > .05, all).

Conclusion: For individuals with T2D and inadequate glycaemic control despite therapy with SGLT2is ± metformin, liraglutide 1.8 mg would provide an effective treatment intensification option, irrespective of HbA1c, BMI, diabetes duration, insulin resistance determined by HOMA-IR and SGLT2i use duration.

Keywords: GLP-1 analogue; SGLT2 inhibitor; antidiabetic drug; glycaemic control; liraglutide; type 2 diabetes.

Conflict of interest statement

L.B. declares research support from Janssen, Lexicon, Merck, Novo Nordisk and Sanofi; speaker honoraria from Janssen, Novo Nordisk and Sanofi; consultant honoraria from AstraZeneca, Gilead, Janssen, Merck, Novo Nordisk and Sanofi. O.M. declares speaker's bureau honoraria and advisory board membership from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk and Sanofi; research support from Novo Nordisk and AstraZeneca. R.R. declares speaker's bureau membership from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck Sharp & Dohme, Novo Nordisk, Sanofi and Takeda; research support from AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk and Sanofi; consulting fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Sanofi. U.F., M.S.K. and C.R. are employees of Novo Nordisk, with M.S.K. and C.R. also holding shares in Novo Nordisk.

© 2021 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.

Figures

FIGURE 1
FIGURE 1
Scatterplot including correlations between overall changes in HbA1c from baseline to week 26 with the addition of liraglutide 1.8 mg versus placebo in patients with type 2 diabetes on stable sodium‐glucose cotransporter‐2 inhibitor therapy ± metformin (trial product estimand). A positive value on the vertical axis represents a reduction in HbA1c. Horizontal axis shows increasing baseline HbA1c values. HbA1c, glycated haemoglobin
FIGURE 2
FIGURE 2
Scatterplots and correlation between overall changes in body weight from baseline to week 26 with the addition of liraglutide 1.8 mg versus placebo in patients with type 2 diabetes on stable sodium‐glucose cotransporter‐2 inhibitor therapy ± metformin (trial product estimand). A positive value on the vertical axis represents a reduction in body weight. Horizontal axis shows increasing baseline BMI values. BMI, body mass index

References

    1. Forouhi NG, Misra A, Mohan V, Taylor R, Yancy W. Dietary and nutritional approaches for prevention and management of type 2 diabetes. BMJ. 2018;361:k2234.
    1. Buse JB, Wexler DJ, Tsapas A, et al. 2019 Update to: Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD). Diabetes Care. 2020;43:487.
    1. American Diabetes Association . 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2021. Diabetes Care. 2021;44:S111‐S124.
    1. Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm ‐ 2020 executive summary. Endocr Pract. 2020;26:107‐139.
    1. Nauck MA, Meier JJ. GLP‐1 receptor agonists and SGLT2 inhibitors: a couple at last? Lancet Diabetes Endocrinol. 2016;4:963‐964.
    1. Ni L, Yuan C, Chen G, Zhang C, Wu X. SGLT2i: beyond the glucose‐lowering effect. Cardiovasc Diabetol. 2020;19:98.
    1. Sheahan KH, Wahlberg EA, Gilbert MP. An overview of GLP‐1 agonists and recent cardiovascular outcomes trials. Postgrad Med J. 2020;96:156‐161.
    1. Frias JP, Guja C, Hardy E, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION‐8): a 28‐week, multicentre, double‐blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2016;4:1004‐1016.
    1. Ludvik B, Frias JP, Tinahones FJ, et al. Dulaglutide as add‐on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD‐10): a 24‐week, randomised, double‐blind, placebo‐controlled trial. Lancet Diabetes Endocrinol. 2018;6:370‐381.
    1. Zinman B, Bhosekar V, Busch R, et al. Semaglutide once weekly as add‐on to SGLT‐2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo‐controlled trial. Lancet Diabetes Endocrinol. 2019;7:356‐367.
    1. Blonde L, Belousova L, Fainberg U, et al. Liraglutide as ADD‐on to sodium‐glucose co‐transporter‐2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA‐ADD2SGLT2i, a 26‐week, randomized, double‐blind, placebo‐controlled trial. Diabetes Obes Metab. 2020;22:929‐937.
    1. Rosenstock J, Jelaska A, Zeller C, Kim G, Broedl UC, Woerle HJ. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial. Diabetes Obes Metab. 2015;17:936‐948.
    1. Pratley RE, Nauck M, Bailey T, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26‐week, randomised, parallel‐group, open‐label trial. Lancet. 2010;375:1447‐1456.
    1. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26‐week randomised, parallel‐group, multinational, open‐label trial (LEAD‐6). Lancet. 2009;374:39‐47.
    1. Potts JE, Gray LJ, Brady EM, Khunti K, Davies MJ, Bodicoat DH. The effect of glucagon‐like peptide 1 receptor agonists on weight loss in type 2 diabetes: a systematic review and mixed treatment comparison meta‐analysis. PLoS One. 2015;10:e0126769.
    1. Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol. 2016;4:525‐536.
    1. DeFronzo RA. Combination therapy with GLP‐1 receptor agonist and SGLT2 inhibitor. Diabetes Obes Metab. 2017;19:1353‐1362.
    1. Wilding J, Godec T, Khunti K, et al. Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second‐line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink. BMC Med. 2018;16:116‐116.
    1. Aroda VA‐O, Capehorn MS, Chaykin L, et al. Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: a patient‐level, pooled analysis of the SUSTAIN 1‐5 trials. Diabetes Obes Metab. 2020;22:303‐314.
    1. Dahlqvist S, Ahlén E, Filipsson K, et al. Variables associated with HbA1c and weight reductions when adding liraglutide to multiple daily insulin injections in persons with type 2 diabetes (MDI liraglutide trial 3). BMJ Open Diabetes Res Care. 2018;6:e000464.
    1. Ostawal A, Mocevic E, Kragh N, Xu W. Clinical effectiveness of liraglutide in type 2 diabetes treatment in the real‐world setting: a systematic literature review. Diabetes Ther. 2016;7:411‐438.
    1. Chitnis AS, Ganz ML, Benjamin N, Langer J, Hammer M. Clinical effectiveness of liraglutide across body mass index in patients with type 2 diabetes in the United States: a retrospective cohort study. Adv Ther. 2014;31:986‐999.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren